Senzime develops and markets unique CE marked and FDA approved medical device solutions, driven by unique algorithms and sensors for bedside monitoring of anesthesia. TetraGraph is a system that measures the level of neuromuscular blockade digitally and continuously to prevent complications, improve clinical precision and simplify management of care. TetraGraph helps prevent complications and enables health care staff to comply with guidelines and drug recommendations, thus helping shorten hospital stays and cut health care costs. Senzime’s vision is a world without anesthesiarelated complications, and safe emergence from anesthesia for all patients. Senzime operates on expansive markets worth in excess of SEK 10 billion in Europe and the US alone.
TetraGraph Quantitative Neuromuscular Blockade Monitoring- Senzime´s innovative device, TetraGraph, supports the optimization of patient management in patients receiving neuromuscular blocking agents (NMBAs). TetraGraph can be used from start to finish during the surgical procedure. The monitor enables objective assessment of the depth of block and titration of medication dosage to help determine when the patient has recovered sufficiently to maintain spontaneous breathing.
The Senzime AB (publ) share are listed on Nasdaq Stockholm’s main market since June, 30 2021. Short name: SEZI.
The TetraGraph device fulfils the requirements for CE marking (CE 2797)
Senzime AB is located in Uppsala, Sweden.
Residual Neuromuscular Blockade
Qualitative vs Quantitative Monitoring
The new Gold Standard